AtaiBeckley appoints Michael Faerm CFO effective March 9, 2026; Johnson becomes CAO

AtaiBeckley Inc.

Michael Faerm appointed CFO of AtaiBeckley, effective March 9, 2026; Anne Johnson becomes Chief Accounting Officer.
Faerm receives $525k base salary, 40% target bonus, option for 1.275M shares, 285k RSUs (4-yr vest), and $85k sign-on bonus.
Severance: 0.75x salary for 9 months; change-in-control: lump sum salary+target bonus plus accelerated equity vesting.
Faerm previously CFO at Viracta Therapeutics, interim CFO at Harpoon Therapeutics, and CFO at Artiva Biotherapeutics.
CEO cites Faerm's experience as BPL-003 nears Phase 3 and other clinical-stage programs advance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.